Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor [Seeking Alpha]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Seeking Alpha
The company's pipeline is advancing with Orelabrutinib, a potential best-in-class BTK inhibitor, and multiple phase 3 MS trials underway or planned. Obexelimab offers competitive advantages over UPLINZA, including a differentiated MOA and self-administered SC dosing, targeting elderly IgG4-RD patients. Upcoming catalysts include BLA/MAA filings for Obexelimab in 2026 and key data readouts in RMS and SLE, supporting recovery potential. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Dragos Condrea/iStock via Getty Images The last time I spoke about Zenas BioPharma, Inc. ZBIO ), it was regarding a Seeking Alpha article entitled " Zenas: Differentiated B-Cell Targeting Drug With Q3 of 2025 Catalys t". Regarding this More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketpl
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIOPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIOGlobeNewswire
- Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News [Yahoo! Finance]Yahoo! Finance
ZBIO
Earnings
- 11/12/25 - Miss
ZBIO
Sec Filings
- 1/14/26 - Form SCHEDULE
- 1/9/26 - Form 4
- 12/19/25 - Form S-8
- ZBIO's page on the SEC website